-
Investors
- News & publications
- Events & presentations
- Corporate governance
- Individual shareholders
- Media
- Careers
- Partners
- Suppliers
Investors
Ensuring sustainable growth
Middle area:
Key facts & figures
Sanofi is a global healthcare company focused on patient needs. Our business includes pharmaceuticals (notably prescription drugs for diabetes, rare diseases, multiple sclerosis and oncology, consumer healthcare products and generics), vaccines and animal health.
Strong financial performance
2014 Net Sales
€33,770m
+4.9% at constant exchange rates (CER)
+2.5% on a reported basis
2014 Business EPS
€5.20
+7.3% at CER
+3.0% on a reported basis
SOLID GROWTH OF MOST BUSINESS AREAS
| 2014 sales by business areas | Change at CER | |
|---|---|---|
| Pharmaceuticals | €27,720M | +4.4% |
| Diabetes | €7,273M | +12.1% |
| Consumer Healthcare* | €3,337M | +16.5% |
| Genzyme** | €2,604M | +24.3% |
| Generics | €1,805M | +16.2% |
| Oncology | €1,401M | -2.5% |
| Established Rx brands | €11,300M | -6.7% |
| Vaccines | €3,974M | +7.2% |
| Animal Health | €2,076M | +6.7% |
* Some products recorded in prescription pharmaceuticals in 2013 were transferred as Consumer Healthcare products and totaled €273m in FY 2013. When excluding this category change, sales of Consumer Healthcare grew +6.8% in FY 2014 at CER
** Rare Diseases and Multiple Sclerosis
A major biopharmaceutical player with an innovative R&D pipeline
€4,824M
invested in R&D in 2014
18 Launches
of new medicines and vaccines expected between 2014 and 2020,
of which 6 underway or imminent in 2015
Right area:
Stock Market
-
Oct 29, 2015 - 05.38 PM
EURONEXT Paris (SAN) €90.99 -2.48% -
Oct 29, 2015 - 04.01 PM
NYSE (SNY) $49.63 -3.61%
IR mobile application
SANOFI IR is available on iPhone, iPad, Apple Watch and Android!
NEW - Section dedicated to Individual Shareholders
IFRIC 21
New interpretation of tax levies - applicable as from January 1st, 2014
IAS19R
Amended Accounting Standard on Employee Benefits (IAS19R) applicable as from January 1st, 2013
- Impact of IAS19R
- Comparative segment results for full year 2011
- Comparative segment results for full year 2012
Historical information on sales and net income
Historical Consolidated Net Sales
- Sales by geographic region for Genzyme key products in 2011
- Historical consolidated net sales by geographic region since 2008
- Historical consolidated pharma sales by geographic region and product since 2008
- Historical consolidated vaccines sales by geographic region since 2008
Merial Integration
Adoption of Business Net Income
- Adoption of Business Net Income as of Q1 2010
- Business Net Income & Reconciliation of Business Net Income to Adjusted Net Income excluding selected items 2009-2008-2007
© Sanofi 2004-2015 - All rights reserved - Update: June 17, 2015
